Amedeo Smart

Free Medical Literature Service


 

Amedeo

Parkinson's Disease

  Free Subscription

Articles published in
PLoS One
    January 2024
  1. KIM M, Kim D, Kang H, Park S, et al
    A machine learning model for prediction of sarcopenia in patients with Parkinson's Disease.
    PLoS One. 2024;19:e0296282.
    >> Share

  2. BRUNI F, Mancuso V, Stramba-Badiale C, Stramba-Badiale M, et al
    Beyond traditional training: Integrating data from semi-immersive VR dual-task intervention in Parkinsonian Syndromes. A study protocol.
    PLoS One. 2024;19:e0294199.
    >> Share

  3. SOKOLOWSKI A, Bhagwat N, Chatelain Y, Dugre M, et al
    Longitudinal brain structure changes in Parkinson's disease: A replication study.
    PLoS One. 2024;19:e0295069.
    >> Share

  4. ESSAWY ESSAWY A, Abou-ElNaga OA, Mehanna RA, Badae NM, et al
    Comparing the effect of intravenous versus intracranial grafting of mesenchymal stem cells against parkinsonism in a rat model: Behavioral, biochemical, pathological and immunohistochemical studies.
    PLoS One. 2024;19:e0296297.
    >> Share

  5. WAWRZICZNY E, Flinois B, Constant E, Brugalle E, et al
    Dealing with the diagnosis of Parkinson's disease and its implications for couple functioning in the early stage: An interpretative phenomenological analysis.
    PLoS One. 2024;19:e0294240.
    >> Share

  6. MEIJER LL, Ruis C, Schielen ZA, Dijkerman HC, et al
    CT-optimal touch and chronic pain experience in Parkinson's Disease; An intervention study.
    PLoS One. 2024;19:e0298345.
    >> Share

  7. TIAN J, Zuo C, Shi J, Ma D, et al
    Peripheral immune cell traits and Parkinson's disease: A Mendelian randomization study.
    PLoS One. 2024;19:e0299026.
    >> Share

  8. MALAGUTI MC, Gios L, Giometto B, Longo C, et al
    Artificial intelligence of imaging and clinical neurological data for predictive, preventive and personalized (P3) medicine for Parkinson Disease: The NeuroArtP3 protocol for a multi-center research study.
    PLoS One. 2024;19:e0300127.
    >> Share

  9. VARGA I, Bakstein E, Gilmore G, May J, et al
    Statistical segmentation model for accurate electrode positioning in Parkinson's deep brain stimulation based on clinical low-resolution image data and electrophysiology.
    PLoS One. 2024;19:e0298320.
    >> Share

  10. SEUTHE J, Heinzel A, Hulzinga F, Ginis P, et al
    Towards a better understanding of anticipatory postural adjustments in people with Parkinson's disease.
    PLoS One. 2024;19:e0300465.
    >> Share

  11. SCHRAG A, Kostev K
    Association of antihypertensives and Parkinson's disease in a primary care population matched for underlying diagnosis.
    PLoS One. 2024;19:e0299985.
    >> Share

    January 2023

  12. Expression of Concern: Progression of Parkinson's disease is associated with gut dysbiosis: Two-year follow-up study.
    PLoS One. 2023;18:e0280116.
    >> Share

  13. ABRAHAM A, Bay AA, Ni L, Schindler N, et al
    Gender differences in motor and non-motor symptoms in individuals with mild-moderate Parkinson's disease.
    PLoS One. 2023;18:e0272952.
    >> Share

  14. MA A, Desai N, Lau KK, Palaniswami M, et al
    Automated measurement of inter-arytenoid distance on 4D laryngeal CT: A validation study.
    PLoS One. 2023;18:e0279927.
    >> Share

  15. LONGARDNER K, Wright BA, Alakkas A, You H, et al
    Assessing the risks of treatment in Parkinson disease psychosis: An in-depth analysis.
    PLoS One. 2023;18:e0278262.
    >> Share

  16. HAPUTHANTHIRIGE NKH, Sullivan K, Moyle G, Brauer S, et al
    Effects of dance on gait and dual-task gait in Parkinson's disease.
    PLoS One. 2023;18:e0280635.
    >> Share

  17. DUARTE JDS, Alcantara WA, Brito JS, Barbosa LCS, et al
    Physical activity based on dance movements as complementary therapy for Parkinson's disease: Effects on movement, executive functions, depressive symptoms, and quality of life.
    PLoS One. 2023;18:e0281204.
    >> Share

  18. CABALLOL N, Bayes A, Prats A, Martin-Baranera M, et al
    Feasibility of a wearable inertial sensor to assess motor complications and treatment in Parkinson's disease.
    PLoS One. 2023;18:e0279910.
    >> Share

  19. GOMEZ LF, Morales A, Fierrez J, Orozco-Arroyave JR, et al
    Exploring facial expressions and action unit domains for Parkinson detection.
    PLoS One. 2023;18:e0281248.
    >> Share

  20. AVENI K, Ahmed J, Borovsky A, McRae K, et al
    Predictive language comprehension in Parkinson's disease.
    PLoS One. 2023;18:e0262504.
    >> Share

  21. MORAITOU M, Sotiroudis G, Papagiannakis N, Ferraz MMJ, et al
    a-Synuclein and lipids in erythrocytes of Gaucher disease carriers and patients before and after enzyme replacement therapy.
    PLoS One. 2023;18:e0277602.
    >> Share

  22. BUCHWITZ TM, Ruppert-Junck MC, Greuel A, Maier F, et al
    Exploring impaired self-awareness of motor symptoms in Parkinson's disease: Resting-state fMRI correlates and the connection to mindfulness.
    PLoS One. 2023;18:e0279722.
    >> Share

  23. CARRICARTE NARANJO C, Sanchez Luaces C, Pedroso Ibanez I, Machado A, et al
    Beyond shallow feelings of complex affect: Non-motor correlates of subjective emotional experience in Parkinson's disease.
    PLoS One. 2023;18:e0281959.
    >> Share

  24. DISMORE L, Montague K, Carvalho L, Guerreiro T, et al
    A protocol for the evaluation of a wearable device for monitoring of symptoms, and cueing for the management of drooling, in people with Parkinson's disease.
    PLoS One. 2023;18:e0280727.
    >> Share

  25. SOOD M, Suenkel U, von Thaler AK, Zacharias HU, et al
    Bayesian network modeling of risk and prodromal markers of Parkinson's disease.
    PLoS One. 2023;18:e0280609.
    >> Share

  26. OHMICHI T, Kasai T, Shinomoto M, Kitani-Morii F, et al
    Serum leucine-rich alpha2 glycoprotein as a potential biomarker for systemic inflammation in Parkinson's disease.
    PLoS One. 2023;18:e0282153.
    >> Share

  27. SEO K, Matunari I, Yamamoto T
    Cerebral cortical thinning in Parkinson's disease depends on the age of onset.
    PLoS One. 2023;18:e0281987.
    >> Share

  28. CHUNG JW, Knight CA, Bower AE, Martello JP, et al
    Rate control deficits during pinch grip and ankle dorsiflexion in early-stage Parkinson's disease.
    PLoS One. 2023;18:e0282203.
    >> Share

  29. CARVAJAL-OLIVEROS A, Dominguez-Baleon C, Sanchez-Diaz I, Zambrano-Tipan D, et al
    Parkinsonian phenotypes induced by Synphilin-1 expression are differentially contributed by serotonergic and dopaminergic circuits and suppressed by nicotine treatment.
    PLoS One. 2023;18:e0282348.
    >> Share

  30. ALI DE, Bassam SM, Elatrebi S, Habiba ES, et al
    HR LC-MS/MS metabolomic profiling of Yucca aloifolia fruit and the potential neuroprotective effect on rotenone-induced Parkinson's disease in rats.
    PLoS One. 2023;18:e0282246.
    >> Share

  31. TAN QY, Roberts HC, Fraser SDS, Amar K, et al
    What are the modifiable factors of treatment burden and capacity among people with Parkinson's disease and their caregivers: A qualitative study.
    PLoS One. 2023;18:e0283713.
    >> Share

  32. VAN DER LIJN I, de Haan GA, van der Feen FE, Huizinga F, et al
    Prevalence and nature of self-reported visual complaints in people with Parkinson's disease-Outcome of the Screening Visual Complaints questionnaire.
    PLoS One. 2023;18:e0283122.
    >> Share

  33. HWANG KS, Langley J, Tripathi R, Hu XP, et al
    In vivo detection of substantia nigra and locus coeruleus volume loss in Parkinson's disease using neuromelanin-sensitive MRI: Replication in two cohorts.
    PLoS One. 2023;18:e0282684.
    >> Share

  34. CAMPI M, Peters GW, Toczydlowska D
    Ataxic speech disorders and Parkinson's disease diagnostics via stochastic embedding of empirical mode decomposition.
    PLoS One. 2023;18:e0284667.
    >> Share

  35. ANWER DM, Gubinelli F, Kurt YA, Sarauskyte L, et al
    A comparison of machine learning approaches for the quantification of microglial cells in the brain of mice, rats and non-human primates.
    PLoS One. 2023;18:e0284480.
    >> Share

  36. ALLWRIGHT M, Mundell H, Sutherland G, Austin P, et al
    Machine learning analysis of the UK Biobank reveals IGF-1 and inflammatory biomarkers predict Parkinson's disease risk.
    PLoS One. 2023;18:e0285416.
    >> Share

  37. MACLAGAN LC, Marras C, Sewell IJ, Wu CF, et al
    Trends in health service use among persons with Parkinson's disease by rurality: A population-based repeated cross-sectional study.
    PLoS One. 2023;18:e0285585.
    >> Share

  38. HIRANO M, Samukawa M, Isono C, Nagai Y, et al
    The effects of safinamide on dysphagia in Parkinson's disease.
    PLoS One. 2023;18:e0286066.
    >> Share

  39. DAS J, Barry G, Walker R, Vitorio R, et al
    The integration of technology into a home-based visuo-cognitive training intervention for people with Parkinson's: Is the future digital?
    PLoS One. 2023;18:e0285100.
    >> Share

  40. ESCHWEILER M, McCrum C, Giannouli E
    A registered report of a crossover study on the effects of face masks on walking adaptability in people with Parkinson's disease and multiple sclerosis.
    PLoS One. 2023;18:e0286402.
    >> Share

  41. CHAND DA, Scadeng M, Dieriks BV
    Absolute quantification of neuromelanin in formalin-fixed human brains using absorbance spectrophotometry.
    PLoS One. 2023;18:e0288327.
    >> Share

  42. MARTINDALE JM, Sarva H, Martino D, Gilbert DL, et al
    Study protocol: A cross-sectional survey of clinicians to identify barriers to clinical practice guideline implementation in the assessment and treatment of persistent tic disorders.
    PLoS One. 2023;18:e0288408.
    >> Share

  43. PARAJULI M, Amara AW, Shaban M
    Deep-learning detection of mild cognitive impairment from sleep electroencephalography for patients with Parkinson's disease.
    PLoS One. 2023;18:e0286506.
    >> Share

  44. SORRELL L, Leta V, Barnett A, Stevens K, et al
    Clinical features and outcomes of hospitalised patients with COVID-19 and Parkinsonian disorders: A multicentre UK-based study.
    PLoS One. 2023;18:e0285349.
    >> Share

  45. ZAMORA-URSULO MA, Perez-Becerra J, Tellez LA, Saderi N, et al
    Reversal of pathological motor behavior in a model of Parkinson's disease by striatal dopamine uncaging.
    PLoS One. 2023;18:e0290317.
    >> Share

  46. BRITO SAF, Scianni AA, Silveira BMF, Oliveira ERM, et al
    Effects of high-intensity respiratory muscle training on respiratory muscle strength in individuals with Parkinson's disease: Protocol of a randomized clinical trial.
    PLoS One. 2023;18:e0291051.
    >> Share

  47. CROOKS S, Carter G, Wilson CB, Wynne L, et al
    Exploring public perceptions and awareness of Parkinson's disease: A scoping review.
    PLoS One. 2023;18:e0291357.
    >> Share

  48. CHIU YS, Wu KJ, Yu SJ, Wu KL, et al
    Peptide immunization against the C-terminal of alpha-synuclein reduces locomotor activity in mice overexpressing alpha-synuclein.
    PLoS One. 2023;18:e0291927.
    >> Share

  49. BATTISTA L, Casali M, Brusa L, Radicati FG, et al
    Clinical assessment of a new wearable tool for continuous and objective recording of motor fluctuations and ON/OFF states in patients with Parkinson's disease.
    PLoS One. 2023;18:e0287139.
    >> Share

  50. VOLLSTEDT EJ, Madoev H, Aasly A, Ahmad-Annuar A, et al
    Establishing an online resource to facilitate global collaboration and inclusion of underrepresented populations: Experience from the MJFF Global Genetic Parkinson's Disease Project.
    PLoS One. 2023;18:e0292180.
    >> Share

  51. OKEMUO AJ, Gallagher D, Dairo YM
    Effects of rebound exercises on balance and mobility of people with neurological disorders: A systematic review.
    PLoS One. 2023;18:e0292312.
    >> Share

  52. GUTOWSKI T, Antkiewicz R, Szlufik S
    Machine learning with optimization to create medicine intake schedules for Parkinson's disease patients.
    PLoS One. 2023;18:e0293123.
    >> Share

  53. PADILHA C, Souza R, Grossl FS, Gauer APM, et al
    Physical exercise and its effects on people with Parkinson's disease: Umbrella review.
    PLoS One. 2023;18:e0293826.
    >> Share

  54. THANPRASERTSUK S, Phowthongkum P, Hopetrungraung T, Poorirerngpoom C, et al
    Levodopa-induced dyskinesia in early-onset Parkinson's disease (EOPD) associates with glucocerebrosidase mutation: A next-generation sequencing study in EOPD patients in Thailand.
    PLoS One. 2023;18:e0293516.
    >> Share

  55. LEE SH, Chung KC
    USP7 attenuates endoplasmic reticulum stress-induced apoptotic cell death through deubiquitination and stabilization of FBXO7.
    PLoS One. 2023;18:e0290371.
    >> Share

  56. MCCANN E, Lee S, Coleman F, O'Sullivan JD, et al
    Pareidolias are a function of visuoperceptual impairment.
    PLoS One. 2023;18:e0293942.
    >> Share

  57. O'MALLEY N, Coote S, Staunton FM, O'Connor E, et al
    A core outcome set for evaluating the effectiveness of mixed-diagnosis falls prevention interventions for people with Multiple Sclerosis, Parkinson's Disease and stroke.
    PLoS One. 2023;18:e0294193.
    >> Share

  58. SENA IG, Costa AVD, Santos IKD, Araujo DP, et al
    Feasibility and effect of high-intensity training on the progression of motor symptoms in adult individuals with Parkinson's disease: A systematic review and meta-analysis.
    PLoS One. 2023;18:e0293357.
    >> Share

  59. MAGANA JC, Deus CM, Baldellou L, Avellanet M, et al
    Investigating the impact of physical activity on mitochondrial function in Parkinson's disease (PARKEX): Study protocol for A randomized controlled clinical trial.
    PLoS One. 2023;18:e0293774.
    >> Share

  60. MORADI VASTEGANI S, Khoshnam SE, Ghafouri S, Bakhtiari N, et al
    Anethole attenuates motor dysfunctions, striatal neuronal activity deficiency and blood brain barrier permeability by decreasing striatal alpha-synuclein and oxidative stress in rotenone-induced Parkinson's disease of male rats.
    PLoS One. 2023;18:e0294612.
    >> Share

  61. XIN G, Niu J, Tian Q, Fu Y, et al
    Identification of potential immune-related hub genes in Parkinson's disease based on machine learning and development and validation of a diagnostic classification model.
    PLoS One. 2023;18:e0294984.
    >> Share

  62. HONG JT, Jung HK, Lee KJ, Gong EJ, et al
    Potential risk of proton pump inhibitors for Parkinson's disease: A nationwide nested case-control study.
    PLoS One. 2023;18:e0295981.
    >> Share

  63. CHEN L, Xin G, He Y, Tian Q, et al
    Study of molecular patterns associated with ferroptosis in Parkinson's disease and its immune signature.
    PLoS One. 2023;18:e0295699.
    >> Share

  64. BORGHESI F, Mancuso V, Bruni F, Cremascoli R, et al
    Mental flexibility assessment: A research protocol for patients with Parkinson's Disease and Anorexia Nervosa.
    PLoS One. 2023;18:e0293921.
    >> Share

  65. MERCER HM, Nair AM, Ridgel A, Piontkivska H, et al
    Alterations in RNA editing in skeletal muscle following exercise training in individuals with Parkinson's disease.
    PLoS One. 2023;18:e0287078.
    >> Share

  66. HATTORI N, Kabata D, Asada S, Kanda T, et al
    Real-world evidence on levodopa dose escalation in patients with Parkinson's disease treated with istradefylline.
    PLoS One. 2023;18:e0269969.
    >> Share

    January 2022
  67. HASSIN-BAER S, Cohen OS, Israeli-Korn S, Yahalom G, et al
    Identification of an early-stage Parkinson's disease neuromarker using event-related potentials, brain network analytics and machine-learning.
    PLoS One. 2022;17:e0261947.
    >> Share

  68. PAMPHLETT R, Bishop DP
    Mercury is present in neurons and oligodendrocytes in regions of the brain affected by Parkinson's disease and co-localises with Lewy bodies.
    PLoS One. 2022;17:e0262464.
    >> Share

  69. HATTORI N, Takeda A, Hanya Y, Kitagawa T, et al
    Effects of rasagiline on Parkinson's Disease Questionnaire (PDQ-39) emotional well-being domain in patients with Parkinson's disease: A post-hoc analysis of clinical trials in Japan.
    PLoS One. 2022;17:e0262796.
    >> Share

  70. GIGUERE-RANCOURT A, Plourde M, Racine E, Couture M, et al
    Goal management training and psychoeducation / mindfulness for treatment of executive dysfunction in Parkinson's disease: A feasibility pilot trial.
    PLoS One. 2022;17:e0263108.
    >> Share

  71. DIAZ K, Stegemoller EEL
    Electromyographic measures of asymmetric muscle control of swallowing in Parkinson's disease.
    PLoS One. 2022;17:e0262424.
    >> Share

  72. VALKONEN K, Makela JP, Airaksinen K, Nurminen J, et al
    Deep brain stimulation of subthalamic nucleus modulates cortical auditory processing in advanced Parkinson's Disease.
    PLoS One. 2022;17:e0264333.
    >> Share

  73. SHABAN M, Amara AW
    Resting-state electroencephalography based deep-learning for the detection of Parkinson's disease.
    PLoS One. 2022;17:e0263159.
    >> Share

  74. KELEMEN A, Halasz L, Eross L, Rudas G, et al
    Factors affecting postural instability after more than one-year bilateral subthalamic stimulation in Parkinson's disease: A cross-sectional study.
    PLoS One. 2022;17:e0264114.
    >> Share

  75. DISBROW EA, Glassy ND, Dressler EM, Russo K, et al
    Cortical oscillatory dysfunction in Parkinson disease during movement activation and inhibition.
    PLoS One. 2022;17:e0257711.
    >> Share

  76. HSU P, Ready EA, Grahn JA
    The effects of Parkinson's disease, music training, and dance training on beat perception and production abilities.
    PLoS One. 2022;17:e0264587.
    >> Share

  77. GONZALEZ-CASACUBERTA I, Vilas D, Pont-Sunyer C, Tobias E, et al
    Neuronal induction and bioenergetics characterization of human forearm adipose stem cells from Parkinson's disease patients and healthy controls.
    PLoS One. 2022;17:e0265256.
    >> Share

  78. FERRUCCI R, Mameli F, Ruggiero F, Reitano M, et al
    Alternate fluency in Parkinson's disease: A machine learning analysis.
    PLoS One. 2022;17:e0265803.
    >> Share

  79. SCHONENBERG A, Prell T
    Measuring quality of life with the Parkinson's Disease Questionnaire-39 in people with cognitive impairment.
    PLoS One. 2022;17:e0266140.
    >> Share

  80. LUCIEN F, Benarroch EE, Mullan A, Ali F, et al
    Poly (ADP-Ribose) and alpha-synuclein extracellular vesicles in patients with Parkinson disease: A possible biomarker of disease severity.
    PLoS One. 2022;17:e0264446.
    >> Share

  81. GULKE E, Alsalem M, Kirsten M, Vettorazzi E, et al
    Comparison of Montreal cognitive assessment and Mattis dementia rating scale in the preoperative evaluation of subthalamic stimulation in Parkinson's disease.
    PLoS One. 2022;17:e0265314.
    >> Share

  82. KOH J, Takahashi M, Ohmae Y, Taruya J, et al
    A single-arm open-label pilot study of brief mindfulness meditation to control impulsivity in Parkinson's disease.
    PLoS One. 2022;17:e0266354.
    >> Share

  83. RUONALA V, Pekkonen E, Airaksinen O, Kankaanpaa M, et al
    Changes in elbow flexion EMG morphology during adjustment of deep brain stimulator in advanced Parkinson's disease.
    PLoS One. 2022;17:e0266936.
    >> Share

  84. JOVANOVIC P, Wang Y, Vit JP, Novinbakht E, et al
    Sustained chemogenetic activation of locus coeruleus norepinephrine neurons promotes dopaminergic neuron survival in synucleinopathy.
    PLoS One. 2022;17:e0263074.
    >> Share

  85. VIRBEL-FLEISCHMAN C, Retory Y, Hardy S, Huiban C, et al
    Body-Worn Sensors for Parkinson's disease: A qualitative approach with patients and healthcare professionals.
    PLoS One. 2022;17:e0265438.
    >> Share

  86. BAKKER M, Johnson ME, Corre L, Mill DN, et al
    Identifying rates and risk factors for medication errors during hospitalization in the Australian Parkinson's disease population: A 3-year, multi-center study.
    PLoS One. 2022;17:e0267969.
    >> Share

  87. MEDINA CA, Vargas E, Munger SJ, Miller JE, et al
    Vocal changes in a zebra finch model of Parkinson's disease characterized by alpha-synuclein overexpression in the song-dedicated anterior forebrain pathway.
    PLoS One. 2022;17:e0265604.
    >> Share

  88. GRAMOTNEV DK, Gramotnev G, Gramotnev A, Summers MJ, et al
    Path analysis of biomarkers for cognitive decline in early Parkinson's disease.
    PLoS One. 2022;17:e0268379.
    >> Share

  89. TROISI LOPEZ E, Minino R, Sorrentino P, Manzo V, et al
    Sensitivity to gait improvement after levodopa intake in Parkinson's disease: A comparison study among synthetic kinematic indices.
    PLoS One. 2022;17:e0268392.
    >> Share

  90. HILL A, Nantel J
    Sensitivity of discrete symmetry metrics: Implications for metric choice.
    PLoS One. 2022;17:e0268581.
    >> Share

  91. SONG J, Lee JH, Choi J, Suh MK, et al
    Detection and differentiation of ataxic and hypokinetic dysarthria in cerebellar ataxia and parkinsonian disorders via wave splitting and integrating neural networks.
    PLoS One. 2022;17:e0268337.
    >> Share

  92. LANDES RD, Glover A, Pillai L, Doerhoff S, et al
    Levodopa ONOFF-state freezing of gait: Defining the gait and non-motor phenotype.
    PLoS One. 2022;17:e0269227.
    >> Share

  93. ZINNEN AD, Vichich J, Metzger JM, Gambardella JC, et al
    Alpha-synuclein and tau are abundantly expressed in the ENS of the human appendix and monkey cecum.
    PLoS One. 2022;17:e0269190.
    >> Share

  94. CHONG-WEN W, Sha-Sha L, Xu E
    Predictors of rapid eye movement sleep behavior disorder in patients with Parkinson's disease based on random forest and decision tree.
    PLoS One. 2022;17:e0269392.
    >> Share

  95. MARKOVIC V, Stankovic I, Radovanovic S, Petrovic I, et al
    Gait alterations in Parkinson's disease at the stage of hemiparkinsonism-A longitudinal study.
    PLoS One. 2022;17:e0269886.
    >> Share

  96. GOLINSKA PB, Bieleninik L, Harciarek M, Bidzan M, et al
    The impact of cognitive impairment of individuals with Parkinson's disease on their caregivers' mental health: A systematic review protocol.
    PLoS One. 2022;17:e0271480.
    >> Share

  97. LI L, Ji B, Zhao T, Cui X, et al
    The structural changes of gray matter in Parkinson disease patients with mild cognitive impairments.
    PLoS One. 2022;17:e0269787.
    >> Share

  98. READ J, Frost R, Walters K, Tuijt R, et al
    Transitions and challenges for people with Parkinson's and their family members: A qualitative study.
    PLoS One. 2022;17:e0268588.
    >> Share

  99. SONG MK, Adams L, Lee JH, Kim YS, et al
    NXP031 prevents dopaminergic neuronal loss and oxidative damage in the AAV-WT-alpha-synuclein mouse model of Parkinson's disease.
    PLoS One. 2022;17:e0272085.
    >> Share

  100. HILL MA, Bentley SR, Walker TL, Mellick GD, et al
    Does a rare mutation in PTPRA contribute to the development of Parkinson's disease in an Australian multi-incident family?
    PLoS One. 2022;17:e0271499.
    >> Share

  101. HEARN R, Selfe J, Cordero MI, Dobbin N, et al
    The effects of active rehabilitation on symptoms associated with tau pathology: An umbrella review. Implications for chronic traumatic encephalopathy symptom management.
    PLoS One. 2022;17:e0271213.
    >> Share

  102. SONG S, Luo Z, Li C, Huang X, et al
    Depressive symptoms before and after Parkinson's diagnosis-A longitudinal analysis.
    PLoS One. 2022;17:e0272315.
    >> Share

  103. CHEN HC, Wang CY, Chen HH, Liou HH, et al
    Cost-effectiveness of the add-on exenatide to conventional treatment in patients with Parkinson's disease when considering the coexisting effects of diabetes mellitus.
    PLoS One. 2022;17:e0269006.
    >> Share

  104. SHAH R, Read J, Davies N, Nimmons D, et al
    People with Parkinson's perspectives and experiences of self-management: Qualitative findings from a UK study.
    PLoS One. 2022;17:e0273428.
    >> Share

  105. VAN DER LIJN I, de Haan GA, van der Feen FE, Huizinga F, et al
    The Screening Visual Complaints questionnaire (SVCq) in people with Parkinson's disease-Confirmatory factor analysis and advice for its use in clinical practice.
    PLoS One. 2022;17:e0272559.
    >> Share

  106. SNODERLY-FOSTER LJ, Olivas WM
    Regulation of Parkinson's disease-associated genes by Pumilio proteins and microRNAs in SH-SY5Y neuronal cells.
    PLoS One. 2022;17:e0275235.
    >> Share

  107. DAS J, Morris R, Barry G, Vitorio R, et al
    Exploring the feasibility of technological visuo-cognitive training in Parkinson's: Study protocol for a pilot randomised controlled trial.
    PLoS One. 2022;17:e0275738.
    >> Share

  108. BARCENAS R, Fuentes-Garcia R, Naranjo L
    Mixed kernel SVR addressing Parkinson's progression from voice features.
    PLoS One. 2022;17:e0275721.
    >> Share

  109. RAZALI K, Mohd Nasir MH, Othman N, Doolaanea AA, et al
    Characterization of neurobehavioral pattern in a zebrafish 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced model: A 96-hour behavioral study.
    PLoS One. 2022;17:e0274844.
    >> Share

  110. TORRADO JC, Husebo BS, Allore HG, Erdal A, et al
    Digital phenotyping by wearable-driven artificial intelligence in older adults and people with Parkinson's disease: Protocol of the mixed method, cyclic ActiveAgeing study.
    PLoS One. 2022;17:e0275747.
    >> Share

  111. DE GOES MCR, Sarmento A, Lima I, Lyra M, et al
    After-effects of thixotropic conditionings on operational chest wall and compartmental volumes of patients with Parkinson's disease.
    PLoS One. 2022;17:e0275584.
    >> Share

  112. MIKOLAIZAK AS, Rochester L, Maetzler W, Sharrack B, et al
    Connecting real-world digital mobility assessment to clinical outcomes for regulatory and clinical endorsement-the Mobilise-D study protocol.
    PLoS One. 2022;17:e0269615.
    >> Share

  113. BAKER S, Tekriwal A, Felsen G, Christensen E, et al
    Automatic extraction of upper-limb kinematic activity using deep learning-based markerless tracking during deep brain stimulation implantation for Parkinson's disease: A proof of concept study.
    PLoS One. 2022;17:e0275490.
    >> Share

  114. WAIRAGKAR M, Villeneuve E, King R, Janko B, et al
    A novel approach for modelling and classifying sit-to-stand kinematics using inertial sensors.
    PLoS One. 2022;17:e0264126.
    >> Share

  115. LAMA J, Salabasidou E, Volkmann J, Kuzkina A, et al
    Proinflammatory profile in the skin of Parkinson's disease patients with and without pain.
    PLoS One. 2022;17:e0276564.
    >> Share

  116. LOWIT A, Thies T, Steffen J, Scheele F, et al
    Task-based profiles of language impairment and their relationship to cognitive dysfunction in Parkinson's disease.
    PLoS One. 2022;17:e0276218.
    >> Share

  117. OWEN CL, Gaulton C, Roberts HC, Dennison L, et al
    Perceptions of people with Parkinson's and their caregivers of falling and falls-related healthcare services- a qualitative study.
    PLoS One. 2022;17:e0276588.
    >> Share

  118. KOMAGAMINE T, Suzuki K, Kokubun N, Komagamine J, et al
    Sleep-related hallucinations in patients with Parkinson's disease.
    PLoS One. 2022;17:e0276736.
    >> Share


  119. Correction: The Screening Visual Complaints questionnaire (SVCq) in people with Parkinson's disease-Confirmatory factor analysis and advice for its use in clinical practice.
    PLoS One. 2022;17:e0277781.
    >> Share

  120. BEK J, Leventhal D, Groves M, Growcott C, et al
    Moving online: Experiences and potential benefits of digital dance for older adults and people with Parkinson's disease.
    PLoS One. 2022;17:e0277645.
    >> Share

  121. VITORIO R, Morris R, Das J, Walker R, et al
    Brain activity response to cues during gait in Parkinson's disease: A study protocol.
    PLoS One. 2022;17:e0275894.
    >> Share

  122. VAN DER LIJN I, de Haan GA, van der Feen FE, Huizinga F, et al
    Correction: The Screening Visual Complaints questionnaire (SVCq) in people with Parkinson's disease-Confirmatory factor analysis and advice for its use in clinical practice.
    PLoS One. 2022;17:e0278279.
    >> Share

  123. JOLA C, Sundstrom M, McLeod J
    Benefits of dance for Parkinson's: The music, the moves, and the company.
    PLoS One. 2022;17:e0265921.
    >> Share

  124. DIERIKS BV, Highet B, Alik A, Bellande T, et al
    Human pericytes degrade diverse alpha-synuclein aggregates.
    PLoS One. 2022;17:e0277658.
    >> Share

  125. RAJA WK, Neves E, Burke C, Jiang X, et al
    Patient-derived three-dimensional cortical neurospheres to model Parkinson's disease.
    PLoS One. 2022;17:e0277532.
    >> Share

  126. HATORI Y, Kanda Y, Nonaka S, Nakanishi H, et al
    ATP13A2 modifies mitochondrial localization of overexpressed TOM20 to autolysosomal pathway.
    PLoS One. 2022;17:e0276823.
    >> Share

  127. NADEEM H, Zhou B, Goldman D, Romley J, et al
    Association between use of ss2-adrenergic receptor agonists and incidence of Parkinson's disease: Retrospective cohort analysis.
    PLoS One. 2022;17:e0276368.
    >> Share

  128. SHINOHARA M, Yokoi K, Hirayama K, Kanno S, et al
    Mirror writing and cortical hypometabolism in Parkinson's disease.
    PLoS One. 2022;17:e0279007.
    >> Share

  129. OIZUMI H, Sugimura Y, Totsune T, Kawasaki I, et al
    Plasma sphingolipid abnormalities in neurodegenerative diseases.
    PLoS One. 2022;17:e0279315.
    >> Share

  130. OGAWA T, Kajiyama Y, Ishido H, Chiba S, et al
    Decreased cerebrospinal fluid orexin levels not associated with clinical sleep disturbance in Parkinson's disease: A retrospective study.
    PLoS One. 2022;17:e0279747.
    >> Share

    January 2021
  131. BOUSSAC M, Arbus C, Dupouy J, Harroch E, et al
    Personality dimensions of patients can change during the course of parkinson's disease.
    PLoS One. 2021;16:e0245142.
    >> Share

  132. KAMIENIARZ A, Michalska J, Marszalek W, Stania M, et al
    Detection of postural control in early Parkinson's disease: Clinical testing vs. modulation of center of pressure.
    PLoS One. 2021;16:e0245353.
    >> Share

  133. KITANI-MORII F, Kasai T, Horiguchi G, Teramukai S, et al
    Risk factors for neuropsychiatric symptoms in patients with Parkinson's disease during COVID-19 pandemic in Japan.
    PLoS One. 2021;16:e0245864.
    >> Share

  134. SHALASH AS, Hamid E, Elrassas H, Bahbah EI, et al
    Non-motor symptoms in essential tremor, akinetic rigid and tremor-dominant subtypes of Parkinson's disease.
    PLoS One. 2021;16:e0245918.
    >> Share

  135. FORNS J, Layton JB, Bartsch J, Turner ME, et al
    Increased risk of falls and fractures in patients with psychosis and Parkinson disease.
    PLoS One. 2021;16:e0246121.
    >> Share

  136. PARK KH, Sun S, Lim YH, Park HR, et al
    Clinical outcome prediction from analysis of microelectrode recordings using deep learning in subthalamic deep brain stimulation for Parkinson`s disease.
    PLoS One. 2021;16:e0244133.
    >> Share

  137. MAHMOUDZADEH M, Wallois F, Tir M, Krystkowiak P, et al
    Cortical hemodynamic mapping of subthalamic nucleus deep brain stimulation in Parkinsonian patients, using high-density functional near-infrared spectroscopy.
    PLoS One. 2021;16:e0245188.
    >> Share

  138. LIN I, Edison B, Mantri S, Albert S, et al
    Triggers and alleviating factors for fatigue in Parkinson's disease.
    PLoS One. 2021;16:e0245285.
    >> Share

  139. SICA M, Tedesco S, Crowe C, Kenny L, et al
    Continuous home monitoring of Parkinson's disease using inertial sensors: A systematic review.
    PLoS One. 2021;16:e0246528.
    >> Share

  140. OVEISGHARAN S, Yu L, Bennett DA, Buchman AS, et al
    Incident mobility disability, parkinsonism, and mortality in community-dwelling older adults.
    PLoS One. 2021;16:e0246206.
    >> Share

  141. NAGANO T, Kakuma T, Umezu Y, Yanagawa T, et al
    Nutritional status and activities of daily living in patients with Parkinson's disease.
    PLoS One. 2021;16:e0246329.
    >> Share

  142. BURIL J, Burilova P, Pokorna A, Kovacova I, et al
    Representation of Parkinson's disease and atypical Parkinson's syndromes in the Czech Republic-A nationwide retrospective study.
    PLoS One. 2021;16:e0246342.
    >> Share


  143. Retraction: Ectopic Pregnancy-Derived Human Trophoblastic Stem Cells Regenerate Dopaminergic Nigrostriatal Pathway to Treat Parkinsonian Rats.
    PLoS One. 2021;16:e0247151.
    >> Share

  144. LEE JW, Song YS, Kim H, Ku BD, et al
    Patients with scans without evidence of dopaminergic deficit (SWEDD) do not have early Parkinson's disease: Analysis of the PPMI data.
    PLoS One. 2021;16:e0246881.
    >> Share

  145. IIJIMA M, Okuma Y, Suzuki K, Yoshii F, et al
    Associations between probable REM sleep behavior disorder, olfactory disturbance, and clinical symptoms in Parkinson's disease: A multicenter cross-sectional study.
    PLoS One. 2021;16:e0247443.
    >> Share

  146. VARRECCHIA T, Castiglia SF, Ranavolo A, Conte C, et al
    An artificial neural network approach to detect presence and severity of Parkinson's disease via gait parameters.
    PLoS One. 2021;16:e0244396.
    >> Share

  147. AGURTO C, Heisig S, Abrami A, Ho BK, et al
    Parkinson's disease medication state and severity assessment based on coordination during walking.
    PLoS One. 2021;16:e0244842.
    >> Share

  148. BARGIOTAS I, Kalogeratos A, Limnios M, Vidal PP, et al
    Revealing posturographic profile of patients with Parkinsonian syndromes through a novel hypothesis testing framework based on machine learning.
    PLoS One. 2021;16:e0246790.
    >> Share

  149. DZIECIOL K, Iordanishvili E, Abbas Z, Nahimi A, et al
    A robust method for the detection of small changes in relaxation parameters and free water content in the vicinity of the substantia nigra in Parkinson's disease patients.
    PLoS One. 2021;16:e0247552.
    >> Share

  150. JEONG S, Cho H, Kim YJ, Ma HI, et al
    Drug-induced Parkinsonism: A strong predictor of idiopathic Parkinson's disease.
    PLoS One. 2021;16:e0247354.
    >> Share

  151. PHAM U, Skogseid IM, Pripp AH, Boen E, et al
    Impulsivity in Parkinson's disease patients treated with subthalamic nucleus deep brain stimulation-An exploratory study.
    PLoS One. 2021;16:e0248568.
    >> Share

  152. MANTRI S, Klawson E, Albert S, Rapoport R, et al
    The experience of care partners of patients with Parkinson's disease psychosis.
    PLoS One. 2021;16:e0248968.
    >> Share

  153. SEBATE B, Cuttler K, Cloete R, Britz M, et al
    Prioritization of candidate genes for a South African family with Parkinson's disease using in-silico tools.
    PLoS One. 2021;16:e0249324.
    >> Share

  154. LOVEGROVE CJ, Bannigan K
    What is the lived experience of anxiety for people with Parkinson's? A phenomenological study.
    PLoS One. 2021;16:e0249390.
    >> Share

  155. SIRAGY T, Hill A, Nantel J
    Recovery of dynamic stability during slips unaffected by arm swing in people with Parkinson's Disease.
    PLoS One. 2021;16:e0249303.
    >> Share


  156. Correction: A genetic analysis of a Spanish population with early onset Parkinson's disease.
    PLoS One. 2021;16:e0249805.
    >> Share

  157. JENSEN BR, Malling ASB, Schmidt SI, Meyer M, et al
    Long-term treatment with transcranial pulsed electromagnetic fields improves movement speed and elevates cerebrospinal erythropoietin in Parkinson's disease.
    PLoS One. 2021;16:e0248800.
    >> Share

  158. SORBERA C, Brigandi A, Cimino V, Bonanno L, et al
    The impact of SARS-COV2 infection on people in residential care with Parkinson Disease or parkinsonisms: Clinical case series study.
    PLoS One. 2021;16:e0251313.
    >> Share

  159. KROTINGER A, Loui P
    Rhythm and groove as cognitive mechanisms of dance intervention in Parkinson's disease.
    PLoS One. 2021;16:e0249933.
    >> Share

  160. LOLEKHA P, Sriphanom T, Vilaichone RK
    Helicobacter pylori eradication improves motor fluctuations in advanced Parkinson's disease patients: A prospective cohort study (HP-PD trial).
    PLoS One. 2021;16:e0251042.
    >> Share

  161. FREIDLE M, Johansson H, Lebedev AV, Ekman U, et al
    Measuring implicit sequence learning and dual task ability in mild to moderate Parkinson s disease: A feasibility study.
    PLoS One. 2021;16:e0251849.
    >> Share

  162. SHRESTHA S, Parks CG, Richards-Barber M, Chen H, et al
    Parkinson's disease case ascertainment in a large prospective cohort.
    PLoS One. 2021;16:e0251852.
    >> Share

  163. MCKAY JL, Lang KC, Bong SM, Hackney ME, et al
    Abnormal center of mass feedback responses during balance: A potential biomarker of falls in Parkinson's disease.
    PLoS One. 2021;16:e0252119.
    >> Share

  164. RODRIGUEZ-SABATE C, Rodriguez M, Morales I
    Studying the functional connectivity of the primary motor cortex with the binarized cross recurrence plot: The influence of Parkinson's disease.
    PLoS One. 2021;16:e0252565.
    >> Share

  165. BHIDAYASIRI R, Boonmongkol T, Thongchuam Y, Phumphid S, et al
    Correction: Impact of disease stage and age at Parkinson's onset on patients' primary concerns: Insights for targeted management.
    PLoS One. 2021;16:e0252988.
    >> Share

  166. SHENG MZ, Fang TC, Chen YH, Chang MH, et al
    Is either anosmia or constipation associated with cognitive dysfunction in Parkinson's disease?
    PLoS One. 2021;16:e0252451.
    >> Share

  167. CARTER B, Hayes C, Smith A, Pennington A, et al
    A single patient reported outcome measure for acquired brain injury, multiple sclerosis & Parkinson's disease.
    PLoS One. 2021;16:e0251484.
    >> Share

  168. RHEW SH, Kravchenko J, Lyerly HK
    Exposure to low-dose ambient fine particulate matter PM2.5 and Alzheimer's disease, non-Alzheimer's dementia, and Parkinson's disease in North Carolina.
    PLoS One. 2021;16:e0253253.
    >> Share

  169. PEARCE P, Bulluss K, Xu SS, Kim B, et al
    How accurately are subthalamic nucleus electrodes implanted relative to the ideal stimulation location for Parkinson's disease?
    PLoS One. 2021;16:e0254504.
    >> Share

  170. KOYANAGI Y, Fukushi I, Nakamura M, Suzuki K, et al
    The effect of body weight-supported overground gait training for patients with Parkinson's disease: A retrospective case-control observational study.
    PLoS One. 2021;16:e0254415.
    >> Share

  171. TAGUCHI S, Koide H, Oiwa H, Hayashi M, et al
    Antiparkinsonian drugs as potent contributors to nocturnal sleep in patients with Parkinson's disease.
    PLoS One. 2021;16:e0255274.
    >> Share

  172. VACCARI C, Grotto D, Pereira TDV, de Camargo JLV, et al
    GLP-1 and GIP receptor agonists in the treatment of Parkinson's disease: Translational systematic review and meta-analysis protocol of clinical and preclinical studies.
    PLoS One. 2021;16:e0255726.
    >> Share

  173. WARDEN MN, Searles Nielsen S, Camacho-Soto A, Garnett R, et al
    A comparison of prediction approaches for identifying prodromal Parkinson disease.
    PLoS One. 2021;16:e0256592.
    >> Share

  174. ARISTOTELIDOU V, Tsatali M, Overton PG, Vivas AB, et al
    Autonomic factors do not underlie the elevated self-disgust levels in Parkinson's disease.
    PLoS One. 2021;16:e0256144.
    >> Share

  175. BRAKEDAL B, Tzoulis C, Tysnes OB, Haugarvoll K, et al
    NSAID use is not associated with Parkinson's disease incidence: A Norwegian Prescription Database study.
    PLoS One. 2021;16:e0256602.
    >> Share

  176. BARTL M, Dakna M, Galasko D, Hutten SJ, et al
    Biomarkers of neurodegeneration and glial activation validated in Alzheimer's disease assessed in longitudinal cerebrospinal fluid samples of Parkinson's disease.
    PLoS One. 2021;16:e0257372.
    >> Share

  177. PARDOEL S, Shalin G, Lemaire ED, Kofman J, et al
    Grouping successive freezing of gait episodes has neutral to detrimental effect on freeze detection and prediction in Parkinson's disease.
    PLoS One. 2021;16:e0258544.
    >> Share

  178. AOUN K, Double KL, Pearson-Dennett V, Yilmaz R, et al
    Measurement of the adult human midbrain with transcranial ultrasound.
    PLoS One. 2021;16:e0247920.
    >> Share

  179. MA A, Lau KK, Thyagarajan D
    Radiological correlates of vocal fold bowing as markers of Parkinson's disease progression: A cross-sectional study utilizing dynamic laryngeal CT.
    PLoS One. 2021;16:e0258786.
    >> Share

  180. AHN JH, Seok JM, Park J, Jeong H, et al
    Validation of the Korean version of the composite autonomic symptom scale 31 in patients with Parkinson's disease.
    PLoS One. 2021;16:e0258897.
    >> Share

  181. PRELL T, Liebermann JD, Mendorf S, Lehmann T, et al
    Pain coping strategies and their association with quality of life in people with Parkinson's disease: A cross-sectional study.
    PLoS One. 2021;16:e0257966.
    >> Share

  182. BAILEY DK, Clark W, Kosman DJ
    The iron chelator, PBT434, modulates transcellular iron trafficking in brain microvascular endothelial cells.
    PLoS One. 2021;16:e0254794.
    >> Share

  183. NEJTEK VA, James RN, Salvatore MF, Alphonso HM, et al
    Premature cognitive decline in specific domains found in young veterans with mTBI coincide with elder normative scores and advanced-age subjects with early-stage Parkinson's disease.
    PLoS One. 2021;16:e0258851.
    >> Share

  184. SHAMADYKOVA DV, Panteleev DY, Kust NN, Savchenko EA, et al
    Neuroinductive properties of mGDNF depend on the producer, E. Coli or human cells.
    PLoS One. 2021;16:e0258289.
    >> Share

  185. ELFARRASH S, Jensen NM, Ferreira N, Schmidt SI, et al
    Polo-like kinase 2 inhibition reduces serine-129 phosphorylation of physiological nuclear alpha-synuclein but not of the aggregated alpha-synuclein.
    PLoS One. 2021;16:e0252635.
    >> Share

  186. WITT VD, Baur G, Ecke J, Kirchner A, et al
    Parkinson's patients situation during the SARS CoV-2 pandemic and their interest in telemedicine A cross-sectional study.
    PLoS One. 2021;16:e0260317.
    >> Share

  187. DEL PINO R, Murueta-Goyena A, Ayala U, Acera M, et al
    Clinical long-term nocturnal sleeping disturbances and excessive daytime sleepiness in Parkinson's disease.
    PLoS One. 2021;16:e0259935.
    >> Share

  188. RICHARD P, Kozlowski L, Guillorit H, Garnier P, et al
    Queuine, a bacterial-derived hypermodified nucleobase, shows protection in in vitro models of neurodegeneration.
    PLoS One. 2021;16:e0253216.
    >> Share

  189. HAYNES JM, Sibuea SM, Aguiar AA, Li F, et al
    Inhibition of beta-catenin dependent WNT signalling upregulates the transcriptional repressor NR0B1 and downregulates markers of an A9 phenotype in human embryonic stem cell-derived dopaminergic neurons: Implications for Parkinson's disease.
    PLoS One. 2021;16:e0261730.
    >> Share

  190. VIRAMETEEKUL S, Phokaewvarangkul O, Bhidayasiri R
    Profiling the most elderly parkinson's disease patients: Does age or disease duration matter?
    PLoS One. 2021;16:e0261302.
    >> Share

  191. CUBO E, Garcia-Bustillo A, Arnaiz-Gonzalez A, Ramirez-Sanz JM, et al
    Adopting a multidisciplinary telemedicine intervention for fall prevention in Parkinson's disease. Protocol for a longitudinal, randomized clinical trial.
    PLoS One. 2021;16:e0260889.
    >> Share

  192. FRANSSON PA, Nilsson MH, Rehncrona S, Tjernstrom F, et al
    Deep brain stimulation in the subthalamic nuclei alters postural alignment and adaptation in Parkinson's disease.
    PLoS One. 2021;16:e0259862.
    >> Share

  193. MAKAI-BOLONI S, Thijssen E, van Brummelen EMJ, Groeneveld GJ, et al
    Touchscreen-based finger tapping: Repeatability and configuration effects on tapping performance.
    PLoS One. 2021;16:e0260783.
    >> Share

  194. FRANKEMOLLE-GILBERT AM, Howell B, Bower KL, Veltink PH, et al
    Comparison of methodologies for modeling directional deep brain stimulation electrodes.
    PLoS One. 2021;16:e0260162.
    >> Share

    January 2020
  195. GAARE JJ, Nido G, Dolle C, Sztromwasser P, et al
    Meta-analysis of whole-exome sequencing data from two independent cohorts finds no evidence for rare variant enrichment in Parkinson disease associated loci.
    PLoS One. 2020;15:e0239824.
    >> Share

  196. SATO K, Mano T, Iwata A, Toda T, et al
    Autocorrelation-based method to identify disordered rhythm in Parkinson's disease tasks: A novel approach applicable to multimodal devices.
    PLoS One. 2020;15:e0238486.
    >> Share

  197. MONSELLIER E, Bendifallah M, Redeker V, Melki R, et al
    Polypeptides derived from alpha-Synuclein binding partners to prevent alpha-Synuclein fibrils interaction with and take-up by cells.
    PLoS One. 2020;15:e0237328.
    >> Share

  198. GLASS TJ, Kelm-Nelson CA, Szot JC, Lake JM, et al
    Functional characterization of extrinsic tongue muscles in the Pink1-/- rat model of Parkinson disease.
    PLoS One. 2020;15:e0240366.
    >> Share

  199. TANAKA R, Yamashiro K, Ogawa T, Oyama G, et al
    The absence of orthostatic heart rate increase is associated with cognitive impairment in Parkinson's disease.
    PLoS One. 2020;15:e0240491.
    >> Share

  200. KUBOTA M, Kobayashi N, Sugizaki T, Shimoda M, et al
    Carnosine suppresses neuronal cell death and inflammation induced by 6-hydroxydopamine in an in vitro model of Parkinson's disease.
    PLoS One. 2020;15:e0240448.
    >> Share

  201. MORI Y, Yoshikawa E, Futatsubashi M, Ouchi Y, et al
    Neural correlates of standing imagery and execution in Parkinsonian patients: The relevance to striatal dopamine dysfunction.
    PLoS One. 2020;15:e0240998.
    >> Share


  202. Retraction: Conversion of human umbilical cord mesenchymal stem cells in Wharton's jelly to dopamine neurons mediated by the Lmx1a and Neurturin In Vitro: Potential therapeutic application for Parkinson's disease in a rhesus monkey model.
    PLoS One. 2020;15:e0242032.
    >> Share

  203. JENG B, Cederberg KLJ, Lai B, Sasaki JE, et al
    Accelerometer output and its association with energy expenditure in persons with mild-to-moderate Parkinson's disease.
    PLoS One. 2020;15:e0242136.
    >> Share

  204. FAZELI S, Motovali-Bashi M, Peymani M, Hashemi MS, et al
    A compound downregulation of SRRM2 and miR-27a-3p with upregulation of miR-27b-3p in PBMCs of Parkinson's patients is associated with the early stage onset of disease.
    PLoS One. 2020;15:e0240855.
    >> Share

  205. MALINOVA V, Pinter A, Dragaescu C, Rohde V, et al
    The role of intraoperative microelectrode recording and stimulation in subthalamic lead placement for Parkinson's disease.
    PLoS One. 2020;15:e0241752.
    >> Share

  206. MURUGAPPAN M, Alshuaib W, Bourisly AK, Khare SK, et al
    Tunable Q wavelet transform based emotion classification in Parkinson's disease using Electroencephalography.
    PLoS One. 2020;15:e0242014.
    >> Share

  207. BHIDAYASIRI R, Boonmongkol T, Thongchuam Y, Phumphid S, et al
    Impact of disease stage and age at Parkinson's onset on patients' primary concerns: Insights for targeted management.
    PLoS One. 2020;15:e0243051.
    >> Share

  208. PINTO C, Salazar AP, Hennig EM, Kerr G, et al
    Dual-task walking reduces lower limb range of motion in individuals with Parkinson's disease and freezing of gait: But does it happen during what events through the gait cycle?
    PLoS One. 2020;15:e0243133.
    >> Share

  209. BAUMANN-VOGEL H, Hor H, Poryazova R, Valko P, et al
    REM sleep behavior in Parkinson disease: Frequent, particularly with higher age.
    PLoS One. 2020;15:e0243454.
    >> Share

  210. ANDERSSON N, Nilsson MH, Slaug B, Oswald F, et al
    The meaning of home questionnaire revisited: Psychometric analyses among people with Parkinson's disease reveals new dimensions.
    PLoS One. 2020;15:e0242792.
    >> Share

  211. TORTI M, Fossati C, Casali M, De Pandis MF, et al
    Effect of family history, occupation and diet on the risk of Parkinson disease: A case-control study.
    PLoS One. 2020;15:e0243612.
    >> Share

  212. PETROZZIELLO T, Dios AM, Mueller KA, Vaine CA, et al
    SVA insertion in X-linked Dystonia Parkinsonism alters histone H3 acetylation associated with TAF1 gene.
    PLoS One. 2020;15:e0243655.
    >> Share

  213. POLAKOVA K, Ruzicka E, Jech R, Kemlink D, et al
    3D visual cueing shortens the double support phase of the gait cycle in patients with advanced Parkinson's disease treated with DBS of the STN.
    PLoS One. 2020;15:e0244676.
    >> Share

  214. IBRAHIM A, Ali RAR, Manaf MRA, Ahmad N, et al
    Multi-strain probiotics (Hexbio) containing MCP BCMC strains improved constipation and gut motility in Parkinson's disease: A randomised controlled trial.
    PLoS One. 2020;15:e0244680.
    >> Share

  215. SHIM M, Bang WJ, Oh CY, Lee YS, et al
    Risk of dementia and Parkinson's disease in patients treated with androgen deprivation therapy using gonadotropin-releasing hormone agonist for prostate cancer: A nationwide population-based cohort study.
    PLoS One. 2020;15:e0244660.
    >> Share

  216. FAZELI S, Motovali-Bashi M, Peymani M, Hashemi MS, et al
    Correction: A compound downregulation of SRRM2 and miR-27a-3p with upregulation of miR-27b-3p in PBMCs of Parkinson's patients is associated with the early stage onset of disease.
    PLoS One. 2020;15:e0244776.
    >> Share

  217. EHLEN F, Al-Fatly B, Kuhn AA, Klostermann F, et al
    Impact of deep brain stimulation of the subthalamic nucleus on natural language in patients with Parkinson's disease.
    PLoS One. 2020;15:e0244148.
    >> Share

  218. PRAVEEN RAJNEESH C, Liou JC, Hsieh TH, Lin JH, et al
    The voiding efficiency in rat models with dopaminergic brain lesions induced through unilateral and bilateral intrastriatal injections.
    PLoS One. 2020;15:e0243452.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016